This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT02225366 |
|---|---|
| Status | Completed |
| Phase | Phase 1 / Phase 2 |
| Sponsor | M.D. Anderson Cancer Center |
| Enrollment | 4 participants |
| Design | Interventional, Na, Single Group, Masking: None |
| Conditions | Melanoma |
| Interventions | LL37; Photographs |
| Start | Jul 8, 2015 |
| Primary completion | Nov 24, 2020 |
| Study completion | Nov 24, 2020 |
| Results posted | Yes, in the registry |
| Registry last updated | Dec 9, 2021 |
| Collaborators | National Cancer Institute (NCI) |
Compounds on this site that cite this trial
What the registry says the trial is about
The goal of this clinical research study is to find the appropriate dose of LL37 that can be given to patients with melanoma. Researchers also want to learn if LL37 can stimulate the immune system to help control the disease.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Number of Participants With Optimal Biological Dose (OBD) of LL37 Based Upon Toxicity | once a week, up to 8 weeks duration |
1 secondary outcome also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 30, 2026. See the trial changes feed for what has changed recently.
More from M.D. Anderson Cancer Center
Research area: Tissue repair and recovery. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.
